CADL
Candel Therapeutics, Inc.
Price Chart
Latest Quote
$12.85
-0.22 (-1.68%)
Current Price
| Previous Close | $13.07 |
| Open | $12.93 |
| Day High | $13.04 |
| Day Low | $12.60 |
| Volume | 935,599 |
Stock Information
| Shares Outstanding | 76.52M |
| Total Debt | $49.52M |
| Cash Equivalents | $201.56M |
| Net Income | $-88.53M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $983.26M |
| EPS (TTM) | $-1.44 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $831.22M |
| Income | $-88.53M |
| Book/sh | $1.66 |
| Cash/sh | $2.63 |
| Employees | 55 |
Financial Ratios
| Quick Ratio | 15.89 |
| Current Ratio | 16.09 |
| Debt/Eq | 39.26 |
Returns & Margins
| ROA | -28.64% |
| ROE | -81.84% |
Ownership
| Insider Ownership | 14.85% |
| Institutional Ownership | 66.97% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -20.56 |
| P/B | 7.75 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $21.00 |
Technical Indicators
| SMA20 | $12.00 |
| SMA50 | $10.67 |
| SMA200 | $7.23 |
| RSI | 63.99 |
| ATR | 0.9413 |
| Shares Float | 60.06M |
| Short Float | 20.94% |
| Short Ratio | 10.24 |
| Volatility | -0.50 |
| Rel Volume | 0.73 |
Performance History
| Week | -0.08% |
| Month | +28.37% |
| Quarter | +51.00% |
| 6 Months | +151.47% |
| YTD | +136.21% |
| Year | +120.79% |
| 3 Years | +896.12% |
| 5 Years | +62.04% |
| 10 Years | +83.57% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-09-01 | $12.85 | 935,600 |
| 2026-08-31 | $13.07 | 895,000 |
| 2026-08-28 | $13.07 | 1,235,900 |
| 2026-08-27 | $13.75 | 1,180,200 |
| 2026-08-26 | $13.28 | 978,000 |
| 2026-08-25 | $13.60 | 1,342,800 |
| 2026-08-24 | $12.86 | 957,300 |
| 2026-08-21 | $13.13 | 1,336,400 |
| 2026-08-20 | $12.35 | 1,541,900 |
| 2026-08-19 | $13.50 | 2,376,800 |
| 2026-08-18 | $12.05 | 786,900 |
| 2026-08-17 | $12.16 | 2,160,900 |
| 2026-08-14 | $11.72 | 2,069,300 |
| 2026-08-13 | $11.80 | 2,152,400 |
| 2026-08-12 | $10.68 | 1,378,900 |
| 2026-08-11 | $10.65 | 857,200 |
| 2026-08-10 | $10.50 | 648,500 |
| 2026-08-07 | $10.59 | 800,800 |
| 2026-08-06 | $10.58 | 1,298,200 |
| 2026-08-05 | $10.46 | 750,400 |
| 2026-08-04 | $10.51 | 1,072,800 |
| 2026-08-03 | $10.07 | 879,400 |
About Candel Therapeutics, Inc.
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
đ° Latest News
Candel Therapeutics (CADL) Is Up 5.4% After Steep Q2 Loss Widening Has The Bull Case Changed?
Simply Wall St. âĸ 2026-08-21T20:09:18Z
Candel Therapeutics (CADL) Faces Bigger Losses As Its Valuation Still Looks Pricey
Simply Wall St. âĸ 2026-08-20T16:14:52Z
CADL Rises As Biotech Eyes First Commercial Product in 2027 â CEO Points To âMeaningful Executionâ Toward BLA Submission In Q4
Stocktwits âĸ 2026-08-13T19:27:38Z
CADL Stock In Focus As Candel Nears Year-End BLA Filing For Prostate Cancer Drug â Eyes $10â$16B Opportunity
Stocktwits âĸ 2026-08-12T19:08:32Z
Candel Therapeutics Eyes 2026 Prostate Cancer Filing as Lung Study Ramps Up
MarketBeat âĸ 2026-08-12T17:04:55Z
CADL Stock Heads For Biggest Monthly Gains Since December 2024 â Retail Says âOur SLS Days Are Comingâ
Stocktwits âĸ 2026-06-30T16:27:42Z
Candel Therapeutics Designates Mark Sims as CCO
Exec Edge âĸ 2026-06-25T19:53:58Z
CADL Stock Heads For Best Week In A Month â Hereâs Why Retail Is Bullish
Stocktwits âĸ 2026-06-05T10:23:40Z
Candel Therapeutics Eyes Year-End BLA After Strong Prostate Cancer Data
MarketBeat âĸ 2026-05-20T15:13:00Z
Wall Street Analysts Believe Candel Therapeutics (CADL) Could Rally 148.48%: Here's is How to Trade
Zacks âĸ 2026-05-19T13:55:03Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $125,000 |
| Operating Revenue | $0 | $0 | $0 | $125,000 |
| Expenses | ||||
| Interest Expense | $2,119,000 | $2,090,000 | $2,595,000 | $1,708,000 |
| Total Expenses | $48,177,000 | $33,371,000 | $38,391,000 | $34,799,000 |
| Rent Expense Supplemental | $194,000 | $192,000 | $161,000 | $184,000 |
| Other Income Expense | $8,199,000 | $-20,802,000 | $966,000 | $16,370,000 |
| Net Non Operating Interest Income Expense | $1,796,000 | $-1,004,000 | $-514,000 | $-490,000 |
| Interest Expense Non Operating | $2,119,000 | $2,090,000 | $2,595,000 | $1,708,000 |
| Operating Expense | $48,177,000 | $33,371,000 | $38,391,000 | $34,799,000 |
| Other Operating Expenses | $-89,000 | - | - | $-48,000 |
| General And Administrative Expense | $17,770,000 | $14,057,000 | $13,885,000 | $14,060,000 |
| Total Other Finance Cost | - | - | - | $490,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-38,182,000 | $-55,177,000 | $-37,939,000 | $-18,794,000 |
| Net Interest Income | $1,796,000 | $-1,004,000 | $-514,000 | $-490,000 |
| Interest Income | $3,915,000 | $1,086,000 | $2,081,000 | $1,218,000 |
| Normalized Income | $-46,381,000 | $-34,375,000 | $-38,905,000 | $-35,164,000 |
| Net Income From Continuing And Discontinued Operation | $-38,182,000 | $-55,177,000 | $-37,939,000 | $-18,794,000 |
| Total Operating Income As Reported | $-48,266,000 | $-33,371,000 | $-38,391,000 | $-34,722,000 |
| Net Income Common Stockholders | $-38,182,000 | $-55,177,000 | $-37,939,000 | $-18,794,000 |
| Net Income | $-38,182,000 | $-55,177,000 | $-37,939,000 | $-18,794,000 |
| Net Income Including Noncontrolling Interests | $-38,182,000 | $-55,177,000 | $-37,939,000 | $-18,794,000 |
| Net Income Continuous Operations | $-38,182,000 | $-55,177,000 | $-37,939,000 | $-18,794,000 |
| Pretax Income | $-38,182,000 | $-55,177,000 | $-37,939,000 | $-18,794,000 |
| Interest Income Non Operating | $3,915,000 | $1,086,000 | $2,081,000 | $1,218,000 |
| Operating Income | $-48,177,000 | $-33,371,000 | $-38,391,000 | $-34,674,000 |
| Per Share | ||||
| Diluted EPS | $-0.72 | $-1.74 | $-1.31 | $-0.65 |
| Basic EPS | $-0.72 | $-1.74 | $-1.31 | $-0.65 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-43,417,000 | $-31,295,000 | $-35,350,000 | $-32,678,000 |
| Total Unusual Items | $8,199,000 | $-20,802,000 | $966,000 | $16,370,000 |
| Total Unusual Items Excluding Goodwill | $8,199,000 | $-20,802,000 | $966,000 | $16,370,000 |
| Reconciled Depreciation | $845,000 | $990,000 | $960,000 | $778,000 |
| EBITDA (Bullshit earnings) | $-35,218,000 | $-52,097,000 | $-34,384,000 | $-16,308,000 |
| EBIT | $-36,063,000 | $-53,087,000 | $-35,344,000 | $-17,086,000 |
| Diluted Average Shares | $52,958,644 | $31,675,076 | $28,935,289 | $28,823,480 |
| Basic Average Shares | $52,958,644 | $31,675,076 | $28,935,289 | $28,823,480 |
| Diluted NI Availto Com Stockholders | $-38,182,000 | $-55,177,000 | $-37,939,000 | $-18,794,000 |
| Gain On Sale Of Security | $8,199,000 | $-20,802,000 | $966,000 | $16,370,000 |
| Research And Development | $30,496,000 | $19,314,000 | $24,506,000 | $20,787,000 |
| Selling General And Administration | $17,770,000 | $14,057,000 | $13,885,000 | $14,060,000 |
| Other Gand A | $8,944,000 | $5,846,000 | $4,395,000 | $4,262,000 |
| Insurance And Claims | $988,000 | $1,188,000 | $1,597,000 | $2,384,000 |
| Rent And Landing Fees | $194,000 | $192,000 | $161,000 | $184,000 |
| Salaries And Wages | $7,644,000 | $6,831,000 | $7,732,000 | $7,230,000 |
Fetched: 2026-08-31
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $51,922,000 | $66,327,000 | $12,745,000 | $47,714,000 |
| Total Assets | $125,195,000 | $106,866,000 | $41,201,000 | $77,691,000 |
| Total Non Current Assets | $3,806,000 | $3,062,000 | $4,404,000 | $5,746,000 |
| Other Non Current Assets | $503,000 | $329,000 | $382,000 | $266,000 |
| Current Assets | $121,389,000 | $103,804,000 | $36,797,000 | $71,945,000 |
| Other Current Assets | $1,658,000 | $1,150,000 | $1,384,000 | $1,887,000 |
| Cash Cash Equivalents And Short Term Investments | $119,731,000 | $102,654,000 | $35,413,000 | $70,058,000 |
| Cash And Cash Equivalents | $119,731,000 | $102,654,000 | $35,413,000 | $70,058,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $49,034,000 | $13,471,000 | $22,762,000 | $22,800,000 |
| Long Term Debt And Capital Lease Obligation | $48,589,000 | $3,010,000 | $13,356,000 | $22,336,000 |
| Long Term Debt | $47,130,000 | $2,603,000 | $12,383,000 | $20,850,000 |
| Current Debt And Capital Lease Obligation | $445,000 | $10,461,000 | $9,406,000 | $464,000 |
| Current Debt | - | $9,895,000 | $8,893,000 | - |
| Other Current Borrowings | - | $9,895,000 | $8,893,000 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $73,273,000 | $40,539,000 | $28,456,000 | $29,977,000 |
| Total Non Current Liabilities Net Minority Interest | $64,276,000 | $3,010,000 | $14,272,000 | $24,362,000 |
| Derivative Product Liabilities | $15,598,000 | $0 | $916,000 | $1,882,000 |
| Non Current Deferred Liabilities | $89,000 | $0 | $0 | $144,000 |
| Current Liabilities | $8,997,000 | $37,529,000 | $14,184,000 | $5,615,000 |
| Other Current Liabilities | $89,000 | $21,718,000 | - | $48,000 |
| Payables And Accrued Expenses | $8,463,000 | $5,350,000 | $4,778,000 | $5,103,000 |
| Payables | $1,129,000 | $237,000 | $422,000 | $380,000 |
| Accounts Payable | $1,129,000 | $237,000 | $422,000 | $380,000 |
| Equity | ||||
| Common Stock Equity | $51,922,000 | $66,327,000 | $12,745,000 | $47,714,000 |
| Total Equity Gross Minority Interest | $51,922,000 | $66,327,000 | $12,745,000 | $47,714,000 |
| Stockholders Equity | $51,922,000 | $66,327,000 | $12,745,000 | $47,714,000 |
| Retained Earnings | $-230,387,000 | $-192,205,000 | $-137,028,000 | $-99,089,000 |
| Preferred Securities Outside Stock Equity | - | - | - | - |
| Other | ||||
| Treasury Shares Number | $122,608 | $122,608 | $122,608 | $122,608 |
| Ordinary Shares Number | $54,898,303 | $46,810,480 | $29,091,019 | $28,919,810 |
| Share Issued | $55,020,911 | $46,933,088 | $29,213,627 | $29,042,418 |
| Tangible Book Value | $51,922,000 | $66,327,000 | $12,745,000 | $47,714,000 |
| Invested Capital | $99,052,000 | $78,825,000 | $34,021,000 | $68,564,000 |
| Working Capital | $112,392,000 | $66,275,000 | $22,613,000 | $66,330,000 |
| Capital Lease Obligations | $1,904,000 | $973,000 | $1,486,000 | $1,950,000 |
| Total Capitalization | $99,052,000 | $68,930,000 | $25,128,000 | $68,564,000 |
| Treasury Stock | $448,000 | $448,000 | $448,000 | $448,000 |
| Additional Paid In Capital | $282,207,000 | $258,511,000 | $149,931,000 | $146,961,000 |
| Capital Stock | $550,000 | $469,000 | $290,000 | $290,000 |
| Common Stock | $550,000 | $469,000 | $290,000 | $290,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $89,000 | $0 | $0 | $144,000 |
| Long Term Capital Lease Obligation | $1,459,000 | $407,000 | $973,000 | $1,486,000 |
| Current Capital Lease Obligation | $445,000 | $566,000 | $513,000 | $464,000 |
| Current Accrued Expenses | $7,334,000 | $5,113,000 | $4,356,000 | $4,723,000 |
| Net PPE | $3,303,000 | $2,733,000 | $4,022,000 | $5,480,000 |
| Accumulated Depreciation | $-3,558,000 | $-3,076,000 | $-2,089,000 | $-1,129,000 |
| Gross PPE | $6,861,000 | $5,809,000 | $6,111,000 | $6,609,000 |
| Leases | $3,008,000 | $3,109,000 | $3,109,000 | $3,057,000 |
| Other Properties | $3,467,000 | $2,456,000 | $2,755,000 | $3,312,000 |
| Machinery Furniture Equipment | $386,000 | $244,000 | $247,000 | $240,000 |
| Properties | $0 | $0 | $0 | $0 |
| Line Of Credit | - | - | - | - |
| Construction In Progress | - | - | - | - |
Fetched: 2026-08-31
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-38,898,000 | $-27,039,000 | $-34,701,000 | $-32,716,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-38,311,000 | $-27,023,000 | $-34,244,000 | $-31,419,000 |
| Cash Flow From Continuing Operating Activities | $-38,311,000 | $-27,023,000 | $-34,244,000 | $-31,419,000 |
| Operating Gains Losses | $-7,893,000 | $20,802,000 | $-887,000 | $-16,370,000 |
| Investing Activities | ||||
| Capital Expenditure | $-587,000 | $-16,000 | $-457,000 | $-1,297,000 |
| Investing Cash Flow | $-560,000 | $-16,000 | $-280,000 | $-1,297,000 |
| Cash Flow From Continuing Investing Activities | $-560,000 | $-16,000 | $-280,000 | $-1,297,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $19,369,000 | $101,758,000 | $0 | $0 |
| Financing Cash Flow | $56,098,000 | $94,280,000 | $-121,000 | $19,974,000 |
| Cash Flow From Continuing Financing Activities | $56,098,000 | $94,280,000 | $-121,000 | $19,974,000 |
| Net Common Stock Issuance | $19,369,000 | $101,758,000 | $0 | $0 |
| Common Stock Issuance | $19,369,000 | $101,758,000 | $0 | $0 |
| Net Other Financing Charges | - | - | $-121,000 | - |
| Other | ||||
| Repayment Of Debt | $-11,733,000 | $-9,167,000 | $0 | - |
| Issuance Of Debt | $47,946,000 | $0 | $0 | $19,910,000 |
| Interest Paid Supplemental Data | $1,280,000 | $1,795,000 | $2,148,000 | $1,152,000 |
| End Cash Position | $120,147,000 | $102,920,000 | $35,679,000 | $70,324,000 |
| Beginning Cash Position | $102,920,000 | $35,679,000 | $70,324,000 | $83,066,000 |
| Changes In Cash | $17,227,000 | $67,241,000 | $-34,645,000 | $-12,742,000 |
| Proceeds From Stock Option Exercised | $516,000 | $1,689,000 | $0 | $64,000 |
| Net Issuance Payments Of Debt | $36,213,000 | $-9,167,000 | $0 | $19,910,000 |
| Net Long Term Debt Issuance | $36,213,000 | $-9,167,000 | $0 | $19,910,000 |
| Long Term Debt Payments | $-11,733,000 | $-9,167,000 | $0 | - |
| Long Term Debt Issuance | $47,946,000 | $0 | $0 | $19,910,000 |
| Net PPE Purchase And Sale | $-560,000 | $-16,000 | $-280,000 | $-1,297,000 |
| Sale Of PPE | $27,000 | $0 | $177,000 | $0 |
| Purchase Of PPE | $-587,000 | $-16,000 | $-457,000 | $-1,297,000 |
| Change In Working Capital | $2,193,000 | $346,000 | $-525,000 | $71,000 |
| Change In Other Working Capital | $178,000 | - | $-192,000 | $67,000 |
| Change In Other Current Liabilities | $-509,000 | $-513,000 | $-464,000 | $-464,000 |
| Change In Other Current Assets | $-24,000 | $53,000 | $-116,000 | $0 |
| Change In Payables And Accrued Expense | $3,056,000 | $572,000 | $-256,000 | $52,000 |
| Change In Accrued Expense | $2,254,000 | $757,000 | $-301,000 | $1,265,000 |
| Change In Payable | $802,000 | $-185,000 | $45,000 | $-1,213,000 |
| Change In Account Payable | $802,000 | $-185,000 | $45,000 | $-1,213,000 |
| Change In Prepaid Assets | $-508,000 | $234,000 | $503,000 | $416,000 |
| Other Non Cash Items | $819,000 | $663,000 | $666,000 | $589,000 |
| Stock Based Compensation | $3,817,000 | $5,312,000 | $3,091,000 | $2,307,000 |
| Asset Impairment Charge | $90,000 | $41,000 | $390,000 | $0 |
| Depreciation Amortization Depletion | $845,000 | $990,000 | $960,000 | $778,000 |
| Depreciation And Amortization | $845,000 | $990,000 | $960,000 | $778,000 |
| Depreciation | $845,000 | $990,000 | $960,000 | $778,000 |
| Gain Loss On Investment Securities | $-8,199,000 | $20,802,000 | $-966,000 | $-16,370,000 |
| Gain Loss On Sale Of PPE | $306,000 | $0 | $79,000 | $0 |
| Net Income From Continuing Operations | $-38,182,000 | $-55,177,000 | $-37,939,000 | $-18,794,000 |
| Income Tax Paid Supplemental Data | - | - | $0 | $183,000 |
| Net Investment Purchase And Sale | - | - | - | - |
| Sale Of Investment | - | - | - | - |
| Purchase Of Investment | - | - | - | - |
Fetched: 2026-08-31